Matches in SemOpenAlex for { <https://semopenalex.org/work/W4220793803> ?p ?o ?g. }
- W4220793803 endingPage "e004316" @default.
- W4220793803 startingPage "e004316" @default.
- W4220793803 abstract "Background The phase 3 CheckMate 214 trial demonstrated higher response rates and improved overall survival with nivolumab plus ipilimumab versus sunitinib in first-line therapy for advanced clear-cell renal cell carcinoma (RCC). An unmet need exists to identify patients with RCC who are most likely to benefit from treatment with nivolumab plus ipilimumab. Methods In exploratory analyses, pretreatment levels of programmed death ligand 1 were assessed by immunohistochemistry. Genomic and transcriptomic biomarkers (including tumor mutational burden and gene expression signatures) were also investigated. Results Biomarkers previously associated with benefit from immune checkpoint inhibitor-containing regimens in RCC were not predictive for survival in patients with RCC treated with nivolumab plus ipilimumab. Analysis of gene expression identified an association between an inflammatory response and progression-free survival with nivolumab plus ipilimumab. Conclusions The exploratory analyses reveal relationships between molecular biomarkers and provide supportive data on how the inflammation status of the tumor microenvironment may be important for identifying predictive biomarkers of response and survival with combination immunotherapy in patients with RCC. Further validation may help to provide biomarker-driven precision treatment for patients with RCC." @default.
- W4220793803 created "2022-04-03" @default.
- W4220793803 creator A5002796183 @default.
- W4220793803 creator A5003892243 @default.
- W4220793803 creator A5003952829 @default.
- W4220793803 creator A5007052233 @default.
- W4220793803 creator A5008519699 @default.
- W4220793803 creator A5031957363 @default.
- W4220793803 creator A5037389732 @default.
- W4220793803 creator A5052720309 @default.
- W4220793803 creator A5059063118 @default.
- W4220793803 creator A5060522543 @default.
- W4220793803 creator A5069417872 @default.
- W4220793803 creator A5082670685 @default.
- W4220793803 creator A5089861374 @default.
- W4220793803 creator A5091176592 @default.
- W4220793803 date "2022-03-01" @default.
- W4220793803 modified "2023-10-17" @default.
- W4220793803 title "Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma" @default.
- W4220793803 cites W1968657935 @default.
- W4220793803 cites W1969963445 @default.
- W4220793803 cites W2110065044 @default.
- W4220793803 cites W2130410032 @default.
- W4220793803 cites W2136859769 @default.
- W4220793803 cites W2152061559 @default.
- W4220793803 cites W2166662937 @default.
- W4220793803 cites W2214074259 @default.
- W4220793803 cites W2222086386 @default.
- W4220793803 cites W2371138393 @default.
- W4220793803 cites W2494860457 @default.
- W4220793803 cites W2516271598 @default.
- W4220793803 cites W2533508881 @default.
- W4220793803 cites W2572174216 @default.
- W4220793803 cites W2614019065 @default.
- W4220793803 cites W2614480329 @default.
- W4220793803 cites W2622867111 @default.
- W4220793803 cites W2725858612 @default.
- W4220793803 cites W2770781326 @default.
- W4220793803 cites W2774712455 @default.
- W4220793803 cites W2782183686 @default.
- W4220793803 cites W2786987313 @default.
- W4220793803 cites W2792546860 @default.
- W4220793803 cites W2792937256 @default.
- W4220793803 cites W2800869096 @default.
- W4220793803 cites W2805302875 @default.
- W4220793803 cites W2809092757 @default.
- W4220793803 cites W2867868648 @default.
- W4220793803 cites W2897815318 @default.
- W4220793803 cites W2898541856 @default.
- W4220793803 cites W2903686952 @default.
- W4220793803 cites W2913745075 @default.
- W4220793803 cites W2916451481 @default.
- W4220793803 cites W2949644336 @default.
- W4220793803 cites W2952406594 @default.
- W4220793803 cites W2955199260 @default.
- W4220793803 cites W2982698800 @default.
- W4220793803 cites W3011071920 @default.
- W4220793803 cites W3021796372 @default.
- W4220793803 cites W3024966661 @default.
- W4220793803 cites W3029490475 @default.
- W4220793803 cites W3042095160 @default.
- W4220793803 cites W3047001933 @default.
- W4220793803 cites W3081958456 @default.
- W4220793803 cites W3083058958 @default.
- W4220793803 cites W3088499431 @default.
- W4220793803 cites W3096713247 @default.
- W4220793803 cites W3107453141 @default.
- W4220793803 cites W3128607514 @default.
- W4220793803 cites W3134486851 @default.
- W4220793803 cites W3134949580 @default.
- W4220793803 cites W3149557634 @default.
- W4220793803 cites W3198543753 @default.
- W4220793803 cites W4249692483 @default.
- W4220793803 doi "https://doi.org/10.1136/jitc-2021-004316" @default.
- W4220793803 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35304405" @default.
- W4220793803 hasPublicationYear "2022" @default.
- W4220793803 type Work @default.
- W4220793803 citedByCount "37" @default.
- W4220793803 countsByYear W42207938032022 @default.
- W4220793803 countsByYear W42207938032023 @default.
- W4220793803 crossrefType "journal-article" @default.
- W4220793803 hasAuthorship W4220793803A5002796183 @default.
- W4220793803 hasAuthorship W4220793803A5003892243 @default.
- W4220793803 hasAuthorship W4220793803A5003952829 @default.
- W4220793803 hasAuthorship W4220793803A5007052233 @default.
- W4220793803 hasAuthorship W4220793803A5008519699 @default.
- W4220793803 hasAuthorship W4220793803A5031957363 @default.
- W4220793803 hasAuthorship W4220793803A5037389732 @default.
- W4220793803 hasAuthorship W4220793803A5052720309 @default.
- W4220793803 hasAuthorship W4220793803A5059063118 @default.
- W4220793803 hasAuthorship W4220793803A5060522543 @default.
- W4220793803 hasAuthorship W4220793803A5069417872 @default.
- W4220793803 hasAuthorship W4220793803A5082670685 @default.
- W4220793803 hasAuthorship W4220793803A5089861374 @default.
- W4220793803 hasAuthorship W4220793803A5091176592 @default.
- W4220793803 hasBestOaLocation W42207938031 @default.
- W4220793803 hasConcept C121608353 @default.
- W4220793803 hasConcept C126322002 @default.